Diabetes Care: Relationship between serum semicoagulant 3 and coronary heart disease risk in patients with type 1 diabetes in childhood

In a recent study published in Diabetes Care, an authoritative journal in the field of diabetes, researchers aimed to find out whether serum semicoagulant 3 and other inflammatory biomarkers can predict coronary heart disease (CHD) in people with type 1 diabetes in childhood.
population-based national cohort study included 299 people with type 1 diabetes between 1973 and 1982 who were under the age of 15.
they were examined in 2002-2003, with an average age of 33 years (range 21-44) and an average course of diabetes of 24 years (range 19-30).
followed the subjects to the first coronary heart disease event until 31 December 2017.
296 subjects had stored serum samples, and the researchers analyzed their erythra 6 (IL-6), IL-6 subjects, IL-18, hs-CRP, substrate metalloproteinase 9, metalloprotease 1 tissue inhibitors (TIMP-1), semicoagulant 3, and highly sensitive trinin T.
researchers used Cox regression to estimate the CHD-adjusted risk ratio (aHRs) caused by elevated biomarkers per SD.
of the 295 subjects, 40 (13.6%) had CHD events during an average follow-up period of 14.4 years (range 0.5-16).
adjusted for traditional risk factors, IL-6 (aHR is 1.32 (95% CI is 1.09-1.83) and semicoagulant 3 (aHR is 1.44 . 5% CI is 1.09-1.80) and TIMP-1 (aHR is 1.37 (95% CI is 1.04-1.81) are significant predictive indicators of CHD.
it can be seen that there is a significant correlation between semicoagulant 3 and future CHD in patients with type 1 diabetes, and if the results are repeated in larger studies, CHD can be predicted together with conventional risk factors.